Imugene (ASX:IMU) partnered with biotechnology company JW Therapeutics (Shanghai) to assess the combination therapy of the company's oncolytic virus CF33-CD19, onCARlytics, and JW's CD19 CAR-T cell therapy, Carteyva, in patients with advanced solid tumors, according to a Thursday filing with the Australian bourse.

The collaboration involves preclinical studies, both in vitro and in vivo, leading to a first-phase investigator-initiated trial conducted in China, the filing said.

Imugene shares rose 3% in afternoon trade on Thursday.